Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Asset disposition
Quarterly results
scPharmaceuticals Inc. (SCPH) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/10/2023 8-K Quarterly results
Docs: "scPharmaceuticals Inc. Reports Second Quarter 2023 Financial Results and Provides Business Update"
06/08/2023 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
06/07/2023 8-K Other Events  Interactive Data
05/10/2023 8-K Quarterly results
Docs: "scPharmaceuticals Inc. Reports First Quarter 2023 Financial Results and Provides Business Update"
03/22/2023 8-K Quarterly results
Docs: "scPharmaceuticals Inc. Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Business Update"
03/10/2023 8-K Other Events  Interactive Data
12/19/2022 8-K Quarterly results
11/23/2022 8-K Quarterly results
11/09/2022 8-K Quarterly results
10/14/2022 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
Docs: "Form of Warrant, issued by the Company to certain lenders, together with a schedule of warrant holders",
"Credit Agreement and Guaranty, by and among scPharmaceuticals Inc., the subsidiary guarantors from time to time party thereto, the lenders from time to time party thereto and Oaktree Fund Administration, LLC, as administrative agent"
08/09/2022 8-K Quarterly results
07/12/2022 8-K Quarterly results
06/15/2022 8-K Quarterly results
05/16/2022 8-K Quarterly results
05/16/2022 8-K Quarterly results
04/11/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "scPharmaceuticals Inc. Announces Resubmission of FUROSCIX ®"
03/22/2022 8-K Quarterly results
Docs: "scPharmaceuticals Inc. Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update"
11/09/2021 8-K Quarterly results
Docs: "scPharmaceuticals Inc. Reports Third Quarter 2021 Financial Results and Provides Business Update"
09/10/2021 8-K Quarterly results
08/11/2021 8-K Quarterly results
07/13/2021 8-K Other Events, Financial Statements and Exhibits
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15 of the Securities Exchange Act of 1934 Date of Report : July 13, 2021 scPharmaceuticals Inc. Delaware 001-38293 46-5184075 2400 District Avenue, Suite 310 Burlington, Massachusetts 01803 Registrant's telephone number, including area code: 517-0730 Not Applicable Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation to the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Excha...",
"scPharmaceuticals Inc. Announces Positive Top-Line Results from FREEDOM-HF Study"
07/01/2021 8-K Other Events, Financial Statements and Exhibits
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15 of the Securities Exchange Act of 1934 Date of Report : July 1, 2021 scPharmaceuticals Inc. Delaware 001-38293 46-5184075 File Number) Identification No.) 2400 District Avenue, Suite 310 Burlington, Massachusetts 01803 Registrant's telephone number, including area code: 517-0730 Not Applicable Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation to the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuan...",
"scPharmaceuticals Inc. Announces Receipt of Written Minutes from Type C Meeting with the FDA Regarding Development of FUROSCIX ®"
06/09/2021 8-K Quarterly results
05/12/2021 8-K Quarterly results
03/23/2021 8-K Quarterly results
03/12/2021 8-K Quarterly results
02/23/2021 8-K Quarterly results
02/17/2021 8-K Quarterly results
12/07/2020 8-K Other Events, Financial Statements and Exhibits
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15 of the Securities Exchange Act of 1934 Date of Report : December 7, 2020 scPharmaceuticals Inc. Delaware 001-38293 46-5184075 File Number) Identification No.) 2400 District Avenue, Suite 310 Burlington, Massachusetts 01803 Registrant's telephone number, including area code: 517-0730 Not Applicable Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation to the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pur...",
"scPharmaceuticals Inc. Receives Complete Response Letter from FDA for FUROSCIX ®"
12/04/2020 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15 of the Securities Exchange Act of 1934 Date of Report : December 4, 2020 scPharmaceuticals Inc. Delaware 001-38293 46-5184075 2400 District Avenue, Suite 310 Burlington, Massachusetts 01803 Registrant's telephone number, including area code: 517-0730 Not Applicable Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation to the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Ex..."
11/16/2020 8-K Quarterly results
Docs: "SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of report : November 16, 2020 SCPHARMACEUTICALS INC. Delaware 001-38293 46-5184075 2400 District Avenue, Suite 310 Burlington, Massachusetts 01803 Registrant's telephone number, including area code: 517-0730",
"scPharmaceuticals Inc. Reports Third Quarter 2020 Financial Results and Provides Business Update"
08/20/2020 8-K Quarterly results
08/13/2020 8-K Quarterly results
07/27/2020 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy